← 產業報告目錄
Extensive Stage Small Cell Lung Cancer Market Size, Share & Trends Analysis Report By Product Types (Zepzelca (Lurbinectedine), Cosela (Trilaciclib), Tecentriq (Atezolizumab), Imfinzi (Durvalumab)), By Region, And Segment Forecasts, 2023-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-15頁數 179報告編號 INSIGHTACE-43eb61376d
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Industry analysis indicates the Extensive Stage Small Cell Lung Cancer Market globally will develop at a 7.4% CAGR during 2023–2031.
The Extensive Stage Small Cell Lung Cancer sector involves a kind of cancer that affects lung tissue. This domain has witnessed substantial transformation owing to technological breakthroughs and shifting healthcare dynamics.
Several factors contribute to this trajectory, including heightened interest in next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, underpinned by rapid industrialization and expanding end-user bases.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Extensive Stage Small Cell Lung Cancer Market Snapshot
Chapter 4. Global Extensive Stage Small Cell Lung Cancer Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Products, Estimates & Trend Analysis
5.1. By Products, & Market Share, 2022 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following by Products:
5.2.1. Zepzelca (Lurbinectedine)
5.2.2. Cosela (Trilaciclib)
5.2.3. Tecentriq (Atezolizumab)
5.2.4. Imfinzi (Durvalumab)
5.2.5. Other Pipeline Products
5.2.5.1. HLX10 (Serplulimab/Hansizhuang)
5.2.5.2. Socazolimab (ZKAB001)
5.2.5.3. SHR-1316 (Adebrelimab)
5.2.5.4. Tislelizumab
Chapter 6. Extensive Stage Small Cell Lung Cancer Market Segmentation 2: Regional Estimates & Trend Analysis
6.1. North America
6.1.1. North America Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) estimates and forecasts by Products, 2023-2031
6.1.2. North America Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) estimates and forecasts by country, 2023-2031
6.2. Europe
6.2.1. Europe Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) by Products, 2023-2031
6.2.2. Europe Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) by country, 2023-2031
6.3. Asia Pacific
6.3.1. Asia Pacific Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) by Products, 2023-2031
6.3.2. Asia Pacific Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) by country, 2023-2031
6.4. Latin America
6.4.1. Latin America Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) by Products, (US$ Million) 2023-2031
6.4.2. Latin America Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) by country, 2023-2031
6.5. Middle East & Africa
6.5.1. Middle East & Africa Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) by Products, (US$ Million) 2023-2031
6.5.2. Middle East & Africa Extensive Stage Small Cell Lung Cancer Market revenue (US$ Million) by country, 2023-2031
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. F. Hoffmann-La Roche Ltd
7.2.2. AstraZeneca PLC
7.2.3. Jazz Pharmaceuticals Plc
7.2.4. G1 Therapeutics Inc.
7.2.5. Shanghai Henlius Biotech, Inc.
7.2.6. Lee's Pharmaceutical Limited
7.2.7. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
7.2.8. Beigene Ltd.
7.2.9. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們